ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ETOPOPHOS
Prostate and other male cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ETOPOPHOS Rx

Generic Name and Formulations:
Etoposide (as phosphate) 100mg/vial; pwd for IV infusion after reconstitution and dilution.

Company:
Bristol-Myers Squibb

Therapeutic Use:

Indications for ETOPOPHOS:

Refractory testicular tumors after appropriate radiation, surgery, and other chemotherapy.

Adult:

See full labeling. Give by IV infusion over 5 to 210 minutes; use doses equivalent to those used for VePesid (eg, 50–100mg/m2 per day on Days 1 through 5 to 100mg/m2 per day on Days 1, 3, 5). Repeat course every 3–4 weeks after recovery (esp. myelosuppression). Toxicity unknown at doses >175mg/m2 per day. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): see full labeling. Consider dose modification if any myelosuppressive effect due to previous radiation, chemotherapy, or in combination with other drugs.

Children:

Not established.

Warnings/Precautions:

Monitor blood (esp. CBCs/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Embryo-fetal toxicity. Advise patients to use effective contraception during therapy and for at least 4 months (males) or 6 months (females) after last dose. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with levamisole, others that inhibit phosphatase activity. May be potentiated by cyclosporine. Antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid). May potentiate warfarin; monitor INR. Additive toxicity with radiation, other cytotoxic therapies.

Pharmacological Class:

Topoisomerase inhibitor.

Adverse Reactions:

Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), asthenia, alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; infertility, others.

How Supplied:

Single-dose vials—1

Indications for ETOPOPHOS:

Small cell lung cancer.

Adult:

See full labeling. Give by IV infusion over 5 to 210 minutes; use doses equivalent to those used for VePesid (eg, 35mg/m2 per day for 4 days to 50mg/m2 per day for 5 days). Repeat course every 3–4 weeks after recovery (esp. myelosuppression). Toxicity unknown at doses >175mg/m2 per day. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): see full labeling. Consider dose modification if any myelosuppressive effect due to previous radiation, chemotherapy, or in combination with other drugs.

Children:

Not established.

Warnings/Precautions:

Monitor blood (esp. CBCs/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Embryo-fetal toxicity. Advise patients to use effective contraception during therapy and for at least 4 months (males) or 6 months (females) after last dose. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with levamisole, others that inhibit phosphatase activity. May be potentiated by cyclosporine. Antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid). May potentiate warfarin; monitor INR. Additive toxicity with radiation, other cytotoxic therapies.

Pharmacological Class:

Topoisomerase inhibitor.

Adverse Reactions:

Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), asthenia, alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; infertility, others.

How Supplied:

Single-dose vials—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs